Iveric stock soars 41% as eye disorder drug Zimura meets main goal in phase 3 trial

Sep. 06, 2022 7:07 AM ETIVERIC bio, Inc. (ISEE)By: Ravikash, SA News Editor5 Comments

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


Iveric bio (NASDAQ:ISEE) said its medicine Zimura met the main goal of a second phase 3 trial called GATHER2 to treat an eye disease called geographic atrophy (GA).

GA is a progressive degeneration of the macula, as part of late-stage age-related

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.